Newleos Therapeutics, Inc.

Newleos Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, in the United States. It was co-founded by Longwood Fund together with seasoned leaders in central nervous system (CNS) drug development. The company's stated mission is to provide a "new dawn" — or "eos" — for the roughly one in eight people worldwide who suffer from mental illness, a reference embedded in its name. Newleos focuses on innovative neuropsychiatric mechanisms of action intended to reduce side effects and improve outcomes relative to the current standard of care. Its pipeline was licensed from Roche and consists of clinical-stage, oral small molecules targeting GABAA-γ1, V1a, TAAR1 and GABAA-α5. These assets are described as having first- or best-in-class potential in the treatment of general anxiety, social anxiety, substance use disorders, and cognitive impairment. The company operates as a private, venture-backed enterprise and is not publicly listed. Its headquarters location in Boston places it within one of the largest life-sciences and biopharmaceutical clusters in the United States. Newleos positions itself at the intersection of neuroscience and psychiatry, pursuing differentiated mechanisms rather than me-too approaches in a therapeutic area that has historically seen limited innovation.

Newleos Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, United States. It was co-founded by Longwood Fund, a healthcare-focused venture capital firm, together with seasoned leaders in CNS drug development. The company's name reflects its mission: to provide a "new dawn" — or "eos" — for the approximately one in eight people worldwide who suffer from mental illness. A defining feature of Newleos is the origin of its pipeline. Rather than developing molecules entirely in-house from discovery, the company licensed a portfolio of neuropsychiatric assets from Roche. This pipeline consists of clinical-stage, oral small molecules targeting GABAA-γ1, V1a, TAAR1 and GABAA-α5. According to the company, these mechanisms of action are innovative and are intended to reduce side effects and improve outcomes compared with the current standard of care. The targeted indications include general anxiety, social anxiety, substance use disorders, and cognitive impairment, with the company describing the assets as having first- or best-in-class potential. Newleos operates as a private, venture-backed company and is not publicly listed. Its Boston base situates it within a major biopharmaceutical and academic research hub. The company's focus on neuropsychiatry places it in a therapeutic area that has historically attracted less innovation relative to oncology or immunology, making differentiated mechanisms such as TAAR1 and GABAA subtype selectivity notable areas of interest in CNS drug development.

• Newleos Therapeutics is co-founded by Longwood Fund and seasoned CNS drug development leaders.

• The company licenses a neuropsychiatric pipeline from Roche, comprising oral small molecules targeting GABAA-γ1, V1a, TAAR1 and GABAA-α5.

Clinical-stage CNS/neuropsychiatry biotech pursuing first- or best-in-class oral small molecules licensed from Roche.

• GABAA-γ1 targeting oral small molecule

  Clinical-stage candidate with potential in general anxiety, social anxiety, substance use disorders, and cognitive impairment.

• V1a targeting oral small molecule

  Clinical-stage candidate with potential in general anxiety, social anxiety, substance use disorders, and cognitive impairment.

• TAAR1 targeting oral small molecule

  Clinical-stage candidate with potential in general anxiety, social anxiety, substance use disorders, and cognitive impairment.

• GABAA-α5 targeting oral small molecule

  Clinical-stage candidate with potential in general anxiety, social anxiety, substance use disorders, and cognitive impairment.

1. 1A new dawn for treatment of mental health conditions - Newleosnewleos.com
2. 2Newleos Therapeutics, Inc. (United States) - Wikidatawikidata.org